Diligence memo · auto-generated · as of July 2, 2026
GIOCOV Ltd
GIOCOV Ltd looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
GIOCOV Ltd operates in Biotechnology, based in London.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
GIOCOV Ltd has raised $1.2M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $7.1M on 2021-05-14.
Most recent recorded round closed around 2021-11-01.
Valuation (modeled)modeled
Provath models GIOCOV Ltd at approximately $23M (range $1.3M–$91M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.13× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 4.7 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 21% of Biotechnology peers (4293 compared).
Modeled value ranks above 30% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.